Literature DB >> 6497088

Characteristics of protective activity of Mycoplasma hyopneumoniae vaccine.

R F Ross, B J Zimmermann-Erickson, T F Young.   

Abstract

Protective activity of Mycoplasma hyopneumoniae vaccines prepared from whole cells or crude extracts was evaluated in an experimentally induced mycoplasmal pneumonia swine model. Swine were obtained at 7 to 10 weeks of age from a surgically derived herd free of porcine mycoplasmas. Vaccines prepared from whole cells, freeze-thaw-saline solution extract, supernate of culture, or saline wash of cells were treated with 0.15% formalin, incorporated with Freund incomplete adjuvant, and administered IM in 2 doses. Twenty-five to 42 days after the 1st dose of vaccine was given, pigs were challenge exposed intratracheally with supernate of lung homogenate containing only M hyopneumoniae. Necropsies were done 27 to 38 days after challenge exposure. For evaluation of protective efficacy of vaccines, determination of proportion of lung with gross lesions gave better results than histologic, fluorescent antibody or mycoplasmal isolation procedures. Whole cell vaccine containing 10(9) color-changing units of M hyopneumoniae, an amount attainable in log-phase cultures, protected swine against development of pneumonia. Whole cells, supernate of culture, and saline wash of cells induced comparable protection. Protective activity of whole cell vaccine resisted heating at 80 C. Extracts prepared according to a freeze-thaw procedure were variable in protective activity and, in some instances, enhanced lesion development.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6497088

Source DB:  PubMed          Journal:  Am J Vet Res        ISSN: 0002-9645            Impact factor:   1.156


  9 in total

1.  The genome sequence of Mycoplasma hyopneumoniae strain 232, the agent of swine mycoplasmosis.

Authors:  F Chris Minion; Elliot J Lefkowitz; Melissa L Madsen; Barbara J Cleary; Steven M Swartzell; Gregory G Mahairas
Journal:  J Bacteriol       Date:  2004-11       Impact factor: 3.490

2.  Identification and mapping of an immunogenic region of Mycoplasma hyopneumoniae p65 surface lipoprotein expressed in Escherichia coli from a cloned genomic fragment.

Authors:  M F Kim; M B Heidari; S J Stull; M A McIntosh; K S Wise
Journal:  Infect Immun       Date:  1990-08       Impact factor: 3.441

3.  Pathogenesis of mycoplasma pneumonia of swine.

Authors:  K W Jericho
Journal:  Can J Vet Res       Date:  1986-01       Impact factor: 1.310

4.  Interaction between Mycoplasma hyopneumoniae and swine influenza virus.

Authors:  E L Thacker; B J Thacker; B H Janke
Journal:  J Clin Microbiol       Date:  2001-07       Impact factor: 5.948

5.  Expression and immunogenicity of Mycoplasma hyopneumoniae heat shock protein antigen P42 by DNA vaccination.

Authors:  Ya-Lei Chen; Shao-Ning Wang; Wen-Jen Yang; Yi-Jiun Chen; Hsi-Hsun Lin; David Shiuan
Journal:  Infect Immun       Date:  2003-03       Impact factor: 3.441

6.  Mycoplasma hyopneumoniae potentiation of porcine reproductive and respiratory syndrome virus-induced pneumonia.

Authors:  E L Thacker; P G Halbur; R F Ross; R Thanawongnuwech; B J Thacker
Journal:  J Clin Microbiol       Date:  1999-03       Impact factor: 5.948

7.  Detection of respiratory pathogens in air samples from acutely infected pigs.

Authors:  Joseph R Hermann; Susan L Brockmeier; Kyoung-Jin Yoon; Jeffrey J Zimmerman
Journal:  Can J Vet Res       Date:  2008-07       Impact factor: 1.310

8.  Increased production of proinflammatory cytokines following infection with porcine reproductive and respiratory syndrome virus and Mycoplasma hyopneumoniae.

Authors:  Roongroje Thanawongnuwech; Brad Thacker; Patrick Halbur; Eileen L Thacker
Journal:  Clin Diagn Lab Immunol       Date:  2004-09

Review 9.  Determinants for swine mycoplasmal pneumonia reproduction under experimental conditions: A systematic review and recursive partitioning analysis.

Authors:  Beatriz Garcia-Morante; Joaquim Segalés; Emmanuel Serrano; Marina Sibila
Journal:  PLoS One       Date:  2017-07-25       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.